Otsuka’s Acquisition of Konica Minolta’s Biomarker Measurement Technology

Jones Day advised Otsuka Pharmaceutical Co. on the deal.

Otsuka Pharmaceutical Co., Ltd. has signed a contract with Konica Minolta Co., Ltd to acquire Konica Minolta’s new high-sensitivity biomarker measurement technology that uses SPFS (surface plasmon field-enhanced fluorescence spectroscopy) technology developed by Konica Minolta. The transaction amount for this asset acquisition has not been disclosed.

Konica Minolta has developed the world’s first SPFS technology for highly sensitive detection of trace proteins. With this technology, medical institutions can measure disease biomarkers in a short time through a simple operation based on insertion of a dedicated cartridge into the measuring device. Otsuka expects to develop an antigen-based measurement system with a level of sensitivity close to that of a PCR (polymerase chain reaction) test.

The Jones Day team was led by Benjamin Lang (Picture) and Harukuni Ito.

Involved fees earner: Harukuni Ito – Jones Day; Benjamin Lang – Jones Day;

Law Firms: Jones Day;

Clients: Otsuka Pharmaceutical Co. Ltd.;

Author: Martina Bellini